Parallax Health Sciences, Inc. PRLX OTC

Parallax Health Sciences, Inc. (PRLX) generated $-2.95M in operating cash flow for fiscal year 2019. After capital expenditures of $2.63K, free cash flow was $-2.95M.

Free cash flow margin was -2292.5% of revenue. Cash conversion ratio was 0.23x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.23x suggests some earnings are non-cash items

Overall SharesGrow Score: 27/100 with 0/7 criteria passed.